Boston Scientific: Poised for Growth at TD Cowen's 45th Annual Health Care Conference

Boston Scientific Corporation (NYSE: BSX) is set to participate in TD Cowen's 45th Annual Health Care Conference, taking place on March 4, 2025. The company will be represented by Dan Brennan, Executive Vice President and Chief Financial Officer, Art Butcher, Executive Vice President and Group President, MedSurg and Asia Pacific, and Kenneth Stein, Senior Vice President and Chief Medical Officer. They will participate in a 30-minute fireside chat with the host analyst, providing an opportunity to discuss the company's strategic initiatives, financial performance, and product pipeline.

Boston Scientific is well-positioned to continue strengthening its performance and enhancing its long-term growth profile. The company is investing in large, high-growth markets, such as Interventional Cardiology (Structural Heart), Rhythm Management (EP), and Peripheral Interventions (Drug Eluting, Venous, Therapeutic Oncology), with the aim of increasing its revenue mix in high (≥8%) and moderate (3-7%) growth markets to 80% by 2022. This strategic focus on adjacent market opportunities will drive future market penetration and growth.



Boston Scientific takes a disciplined and balanced approach to mergers and acquisitions, investing strategically in companies that complement its existing portfolio. This approach has helped the company continue to enhance category leadership and growth. Recent examples of successful business development deals include the acquisition of the AGENT Drug-Coated Balloon, which delivers a therapeutic dose of paclitaxel to treat coronary in-stent restenosis in patients with coronary artery disease, and the HI-PEITHO trial for the EkoSonic Endovascular System, assessing its efficacy in treating pulmonary emboli in combination with anticoagulation.

Boston Scientific's robust pipeline, with 207 products in development across various therapeutic areas, demonstrates the company's commitment to research and development. The company's focus on cardiovascular diseases, cancer, nervous system diseases, digestive system diseases, urologic diseases, male health, nutritional and metabolic diseases, orthopedic diseases, respiratory tract diseases, and women's health highlights its broad range of expertise and potential for future growth.

In conclusion, Boston Scientific's participation in TD Cowen's 45th Annual Health Care Conference presents an opportunity for the company to showcase its innovative medical technologies, pipeline, and overall business strategy to a wide range of stakeholders. By highlighting its strategic focus on high-growth markets, successful track record of business development, and robust pipeline, Boston Scientific can differentiate itself and maintain its competitive edge in the healthcare industry. Investors and industry professionals should pay close attention to the company's presentation, as it may provide valuable insights into its long-term growth prospects and potential investment opportunities.